Texas

A Phase II, open-label, single-arm study of nEoadjuvant zanzalintinib (XL092) Plus nivoLumab in patients with locally advanced and/or surgically challenging clear cell Renal Cell Carcinoma with or without non-measurable metastasis (EXPLORE-RCC)

Hispanic/Latino and non-Hispanic BlAck patients treated with niRaparib and abiraterone acetate plus prednisone for Metastatic hOrmone sensitive prostate cancer with deleterious homologous recombinatioN repair alterations: a phase II, open label studY (HARMONY)  

BRIDGET: Secondary BRain metastases prevention after Isolated intracranial progression on Trastuzumab/Pertuzumab or T-DM1 in patients with aDvanced human epidermal Growth factor receptor 2+ brEast cancer with the addition of Tucatinib

A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer (CANOPY)

Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial (ARCITECT)

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

A Phase II circulating tumor DNA enriched, genomically directed post-neoadjuvant trial for patients with residual triple negative breast cancer (PERSEVERE)

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-naïve EGFR-mutant Locally Advanced or Metastatic NSCLC

Phase II single-arm multi-center study of adjuvant ipilimumab in combination with nivolumab in subjects with high-risk ocular melanoma